This article provides a behind the scenes look at first novel brain cell transplant.
This article conducted a systematic literature review and individual patient data (IPD) meta-analysis to compare the efficacy and tolerability of different artemisinin-based or quinine-based treatments for malaria in pregnant women.
According to an article in Nature Immunology researchers have used CRISPER Cas9 to discover a T-cell and its receptor that could find and kill a wide range of cancerous cells in the lab. While this discovery is the first of its kind, it is in the early stages and needs more research. There is potential in this discovery to identify new forms of cancer treatment.
The US Department of Health and Human Services (HHS) as issued the first Project BioShield contract to fund the development needed to support the expanded use of an existing antibiotic to treat exposure to inhalational anthrax.
Investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC).
Tychan‘s monoclonal antibody candidate treatment for Yellow Fever has successfully completed Phase 1A/1B safety trials in Singapore.
Researchers from McMaster University have manufactured a new antibacterial gel consisting entirely of bacteria-killing viruses. The new gel opens new doors for phage research in the era of antimicrobial resistance.
Yersinia pathogens inject the enzyme YopO into the macrophages of the immune system, preventing the defense cells from digesting the plague bacteria. This article outlines a study done on the ability of YopO to change its shape and confuse the immune system, allowing for a more targeted approach to treatment and possible eradication of Yersinia.
Treatment with BAT® [Botulism Antitoxin Heptavalent (Equine)] was associated with shorter hospital and intensive care unit stays.
The US Department of Health and Human Services (HHS) awarded a contract for $535 to Emergent BioSolutions Inc. for Vaccinia Immune Globulin Intravenous (VIGIV) to be used in the Strategic National Stockpile. VIGIV is the only therapeutic licensed by the US Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination.